This article is more than 5 years old. Information may no longer be current.
Top intervention news from March: Low-risk TAVR, paclitaxel update and more
Cardiology Today’s Intervention compiled a list of the most-read articles posted on Healio.com/Intervention in March. This month, our readers were interested in developments from the American College of Cardiology Scientific Session including the success of transcatheter aortic valve replacement in low-risk patients, the FDA’s examination of paclitaxel-coated devices and much more.
Low-risk TAVR trials represent ‘historic moment’ in care of aortic stenosis
NEW ORLEANS — TAVR — already a mainstay of treatment for intermediate- and high-risk patients with severe aortic stenosis — may soon become the preferred therapy for low-risk patients as well.
AUGUSTUS: Dual therapy with apixaban, P2Y12 inhibitor safe in Afib patients post-ACS or PCI
NEW ORLEANS — New data from the AUGUSTUS trial provide insight on the appropriate antithrombotic regimen after ACS or PCI in patients with atrial fibrillation.
Preliminary FDA analysis finds paclitaxel-related mortality signal
An FDA official announced at a special meeting that the agency’s preliminary analysis of the possible link between paclitaxel-coated devices and mortality showed a signal of a link between the two, but no “smoking gun” to provide definitive proof or pinpoint a cause.
FDA recommends temporary halt to use of paclitaxel-coated devices in most patients with PAD
The FDA warned that using paclitaxel-coated products in the treatment of peripheral arterial disease in the femoropopliteal artery may increase mortality risk.
Role of atherectomy in endovascular interventions up for debate
NEW ORLEANS — Atherectomy appears to have its place in practice, but experts remain somewhat divided over how judiciously the procedure should be used in endovascular interventions.
FDA approves device to close large-bore vascular punctures
The FDA announced that it recently approved a device to close large-bore puncture sites used to obtain vascular access in catheter-based procedures such as abdominal aortic aneurysm repair, TAVR and balloon aortic valvuloplasty.
Balloon-expandable TAVR safe in bicuspid aortic valves
NEW ORLEANS — Patients with bicuspid aortic valves who underwent TAVR with a balloon-expandable valve had similar rates of death and stroke at 1 year compared with patients with tricuspid aortic valves, according to new data highlighted at the American College of Cardiology Scientific Session.
Shorter DAPT duration after PCI improved outcomes at 1 year
NEW ORLEANS — Patients who took dual antiplatelet therapy after PCI for a shorter amount of time while continuing P2Y12 inhibitor monotherapy did not have an increased risk for MI, death or stroke compared with those who took standard therapy for 1 year, according to data from two studies presented at the American College of Cardiology Scientific Session.
BP-lowering effect of renal denervation persists at 6 months in RADIANCE-HTN SOLO
NEW ORLEANS — Endovascular ultrasound renal denervation resulted in BP reductions that were maintained at 6 months, with fewer prescriptions for antihypertension medications needed, compared with a sham procedure in patients with uncontrolled hypertension, researchers reported at the American College of Cardiology Scientific Session.
COAPT: Transcatheter mitral valve replacement brings health status improvements
NEW ORLEANS —Two substudies from the COAPT trial presented at the American College of Cardiology Scientific Session found that patients with moderate-to-severe or severe mitral regurgitation who had transcatheter mitral valve repair and guideline-directed medical therapy had improvements in health status as soon as 1 month.